Data regarding anti–COVID-19 vaccination efficacy in psoriasis patients treated with immune-modulatory medications are scarce.
Objective
This study aims to examine the rate of positive antibody response following BNT162b2 vaccine in those patients.
Methods
BNT162b2-vaccinated and immune modifier–treated psoriatic patients were assigned to serological testing of IgG antibodies to protein S of SARS-CoV-2 after the second vaccination dose by Abbott Architect or Beckman Coulter. Levels ≥ 1 S1 units/mL (S/ml) and > 150 arbitrary units/ml (AU/ml) are considered a positive antibody response, respectively. The antibody levels further analyzed according to the patient’s characteristics and compared to health workers’ controls.
Results
Forty-nine of the 51 patients had a positive antibody response. Overall, patients treated with immune-modulatory medications had antibody levels similar to the control group.
Conclusions
Immune modifier–treated psoriasis patients seem to develop a positive antibody response to the full BNT162b2 vaccination in the vast majority of cases.
DruyanALidarMBrodavkaMLevyIBarzilaiAPavlotskyF. The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons. Dermatol Ther. 2021;34:e14627.
2.
GreshamLMMarzarioBDutzJKirchhofMG. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. J Am Acad Dermatol. 2021;85(2):E89-E90.
3.
PolackFPThomasSJKitchinN, et al.Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.
4.
AmitSRegev-YochayGAfekAKreissYLeshemE. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021;397(10277):875-877.
5.
DaganNBardaNKeptenE, et al.BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412-1423.
6.
FurerVRondaanCHeijstekW, et al.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis2020; 79:39–52.
7.
PappKAHaraouiBKumarD, et al.Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50-74.
8.
KhouryDSCromerDReynaldiAet al.Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211.
9.
SunBFengYMoX, et al.Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940-948.
MuradMHWangZChuHLinL. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation. BMJ. 2019;364:k4817.
14.
CallawayE. The race for coronavirus vaccines: A graphical guide. Nature. 2020;580(7805):576-577.
15.
PlotkinSA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055-1065.
16.
SahinUMuikADerhovanessianE, et al.COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594–599.
17.
JacksonLAAndersonEJRouphaelNG, et al.An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383:1920–1931.
18.
MazziniLMartinuzziDHyseniI, et al.Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples. J Immunol Methods. 2021;489:112937
19.
Covid vaccine Produces More Antibodies than Having the Disease. Israel21cStaff January 19; 2021.
20.
BoyarskyBJWerbelWAAveryRK, et al.Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. J Am Med Assoc. 2021;325(17):1784-1786.
KennedyNAGoodhandJRBewsheaC, et al.Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut2021;70:865–875.
23.
SalinasGFDe RyckeLBarendregtB, et al.Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72:1037–1043.
24.
SimonDTascilarKFagniF, et al.SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis2021;80:1312–1316. annrheumdis-2021-220461. Online ahead of print.
25.
GeisenUMBernerDKTranF, et al.Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis2021:1–6. annrheumdis-2021-220272. doi:10.1136/annrheumdis-2021-220272. Online ahead of print.
26.
HabermanRHHeratiRSSimonD, et al.Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80:1339–1344. annrheumdis-2021-220597. doi:10.1136/annrheumdis-2021-220597. Online ahead of print.
27.
MahilSKBechmanKRaharjaA, et al.The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: A cohort study. Lancet Rheumatol. 2021;3:E627–E637. doi:10.1016/S2665-9913(21)00212-5. Online ahead of print.
